Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
KALA BIO ( (KALA) ) just unveiled an announcement.
On December 4, 2025, KALA BIO, Inc. entered into a securities purchase agreement with an institutional investor to issue and sell 900,000 shares of common stock and pre-funded warrants for up to 9,100,000 shares, raising $10 million in a registered direct offering. The offering closed on December 5, 2025, with H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the net proceeds for debt repayment and general corporate purposes. The agreement includes restrictions on further issuance of common stock for a specified period, impacting KALA’s financial strategy and market operations.
The most recent analyst rating on (KALA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Underperform.
Kala Pharmaceuticals faces significant financial difficulties, marked by declining revenues and heavy reliance on debt, which pose serious risks. The technical analysis reflects a strong downtrend, with the stock being oversold, adding to the negative outlook. Valuation is unattractive due to negative earnings and the lack of a dividend, further weighing down the stock’s appeal.
To see Spark’s full report on KALA stock, click here.
More about KALA BIO
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and severe eye diseases. The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform for biologics-based investigational therapies. Its lead product candidate, KPI-012, is designed for treating persistent corneal epithelial defect (PCED) and has received Orphan Drug and Fast Track designations from the U.S. FDA.
Average Trading Volume: 7,484,596
Technical Sentiment Signal: Sell
Current Market Cap: $7.91M
For detailed information about KALA stock, go to TipRanks’ Stock Analysis page.